Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
 announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Jan. 23, 2017 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in Washington on behalf of certain purchasers of shares of Seattle Genetics, Inc. (NASDAQ:SGEN) over alleged Securities Laws Violations by Seattle Genetics.
Investors who purchased shares of Seattle Genetics, Inc. (NASDAQ: SGEN) have certain options and for certain investors there are short and strict deadlines running. Deadline: March 13, 2017. NASDAQ: SGEN investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that vadastuximab talirine presents a significant risk of fatal hepatotoxicity, that as such, Seattle Genetics had overstated the viability of vadastuximab talirine as an acute myeloid leukemia (AML) treatment, and that as a result of the foregoing, Seattle Genetics’ public statements were materially false and misleading at all relevant times.
On December 27, 2016, Seattle Genetics, Inc. announced that it has received notice from the U.S. Food and Drug Administration (“FDA“) that a clinical hold or partial clinical hold has been placed on several early stage trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia (AML).
Those who purchased Seattle Genetics, Inc. (NASDAQ: SGEN) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
[email protected]
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
